Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer

University of South Florida

Overview

RATIONALE: Losartan potassium may be effective in treating pulmonary fibrosis caused by radiation therapy in patients with non-small cell lung cancer. PURPOSE: This clinical trial is studying losartan to see how well it works in treating pulmonary fibrosis caused by radiation therapy in patients with stage I, stage II, or stage III non-small cell lung cancer.

OBJECTIVES: Primary * To evaluate the effects of losartan potassium on the disease progression in patients with stage I-III non-small cell lung cancer and radiation-induced pulmonary fibrosis. * To determine the feasibility of losartan potassium as a possible treatment for radiation-induced pulmonary fibrosis. Secondary * The evaluate the effects of losartan potassium on the degree of dyspnea, and lung function (FEV\_1 and FVC) in these patients. OUTLINE: This is a multicenter study. Patients receive oral losartan potassium once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo assessment of pulmonary function (e.g., gas movement, lung capacity, and diffusion of gases) by spirometry and dyspnea by the Visual Analog Scale (VAS) at baseline and at weeks 12 and 24.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Conditions

Dyspnea Lung Cancer Pulmonary Complications Radiation Fibrosis

Interventions

LosartanDRUG

50 mg Losartan will be taken daily by subjects for 24 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

INCLUSION CRITERIA: * At least 18 years of age or older * Diagnosed with non-small cell lung cancer stage I, II, IIIa, or IIIb * Diagnosis of radiation-induced pulmonary fibrosis (as defined by National Cancer Institute's Common Terminology Criteria for Adverse Events \[CTCAE\] V3.0 Grade I to Grade III) and within 2 years of the last radiation therapy treatment EXCLUSION CRITERIA: * Patients with a pneumonectomy * Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker * Use of an angiotensin II receptor blocker currently or within 6 months of study entry which include: losartan, valsartan, irbesartan, candesartan, cilexetil, eprosartan mesylate, and telmisartan * Bilateral renal artery stenosis, hereditary or idiopathic angioedema, or uncontrolled hypotension * Patients taking lithium * Currently smoking or smoked within 6 months of study entry * Pregnant, intending to become pregnant or breastfeeding * Baseline systolic blood pressure \< 100 mmHg * History of lung transplant * History of kidney failure or liver disease * Inability to attend clinic visits

Outcomes

Primary Outcomes

Change in carbon monoxide diffusing capacity (DLCO) at 6 months

Time frame: 6 months

Secondary Outcomes

Feasibility of losartan potassium as treatment for radiation-induced pulmonary fibrosis

Time frame: 6 months

Pulmonary function measurements of FEV1 and FVC and dyspnea score at 6 months

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.